Physician profile
Jacquelyn Weber
NPI 1689088155
$5,373.97
in general payments reported to CMS, 2019-2025
27 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $224 · 2021: $209 · 2022: $1,448 · 2023: $889 · 2024: $738 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Entertainment: $26.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.88 |
| Entertainment | $26.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $892.12 | 2021-2025 | Clareon, Argos, Tryptyr |
| Sun Pharmaceutical Industries INC. | $769.55 | 2019-2025 | Cequa |
| Abbvie INC. | $460.55 | 2022-2024 | Ozurdex, Vuity, Lumigan |
| Mallinckrodt Hospital Products INC. | $442.93 | 2022-2024 | Acthar |
| Bausch & Lomb Americas INC. | $413.13 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Biotissue Holdings INC. | $253.53 | 2024-2025 | |
| Dompe US, INC. | $236.22 | 2021-2025 | Oxervate |
| Notal Vision, INC. | $227.40 | 2022 | |
| Apellis Pharmaceuticals, INC. | $216.75 | 2022-2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $206.58 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $151.82 | 2020-2021 | |
| Allergan, INC. | $148.43 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $134.75 | 2020-2022 | |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Horizon Therapeutics Plc | $111.61 | 2023 | Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $105.94 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $88.93 | 2019-2022 | |
| Rxsight INC | $88.76 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $57.30 | 2022-2023 | |
| Harrow Eye, LLC | $51.09 | 2025 | Vevye |
| Thea Pharma INC. | $44.40 | 2023-2025 | Iyuzeh |
| Avedro INC. | $33.39 | 2019 | |
| Amgen INC. | $29.92 | 2025 | Tepezza |
| Optos, INC. | $26.18 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $24.17 | 2022 | |
| Glaukos Corporation | $17.25 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.